CorrectSequence Therapeutics

Shanghai-based gene editing firm CorrectSequence Therapeutics announced it has received a patent from the United States Patent and Trademark Office (USPTO) for its variant base editing (tBE) system, a technology designed to enhance precision and reduce off-target mutations in gene editing. Technology HighlightsThe tBE system integrates a deoxycytidine deaminase inhibitor…